Related Experiment Video

Updated: Jun 2, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Genetically modified tumour vaccines

P Rossner1, J Bubenik, M Indrova

  • 1ACAD SCI CZECH REPUBL,INST MOL GENET,CR-16637 PRAGUE 6,CZECH REPUBLIC. DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN O,DENMARK.

International Journal of Oncology
|May 3, 2011
PubMed

Insights

Genetic modification of sarcoma cells with Interleukin-2 (IL-2) or CD80 genes reduced tumor formation. IL-2 gene insertion proved more effective in suppressing tumor growth and inhibiting existing tumors.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Murine sarcoma MC12 cells were genetically modified to investigate the impact of specific gene insertions on tumor development.
  • The study focused on the genes encoding Interleukin-2 (IL-2) and the CD80 molecule, both known for their roles in immune responses.

Purpose of the Study:

  • To assess the effect of IL-2 and CD80 gene insertion on the tumorigenicity of MC12 sarcoma cells.
  • To compare the efficacy of IL-2 and CD80 gene expression in suppressing tumor growth.
  • To investigate the potential of IL-2 producing cells in inhibiting established tumors.

Main Methods:

  • Gene insertion of IL-2 and CD80 into murine sarcoma MC12 cells.
  • Assessment of tumorigenicity in various genetically modified cell clones.
  • Evaluation of IL-2 production and CD80 expression levels.
  • Analysis of T lymphocyte adhesion to modified sarcoma cells.

Main Results:

  • Most genetically modified MC12 cell clones exhibited reduced tumorigenicity compared to parental cells.
  • Tumorigenicity decreased with increased IL-2 production and CD80 expression.
  • IL-2 gene insertion demonstrated a more potent suppression of tumorigenicity than CD80 gene insertion.
  • IL-2 producing MC12 clones could completely inhibit the tumorigenicity of CD80-expressing MC12 cells when admixed.
  • CD80 gene insertion significantly enhanced the adhesion between MC12 sarcoma cells and syngeneic T lymphocytes.

Conclusions:

  • Genetic engineering of sarcoma cells with IL-2 or CD80 genes can significantly reduce their tumorigenic potential.
  • Interleukin-2 gene modification offers a more effective strategy for tumor suppression compared to CD80 gene modification.
  • IL-2 producing cells hold promise for therapeutic inhibition of established tumors.
  • CD80 expression on sarcoma cells enhances their interaction with T lymphocytes, potentially influencing anti-tumor immunity.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transgenic Plants02:50

Transgenic Plants

Recombinant DNA technology called transgenesis is often used to add a foreign gene or remove a detrimental gene from an organism. Such genetically modified organisms are called transgenic organisms.
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...